Clinical Trial Update: Abemaciclib in Treating Patients With Surgically Resectable, Chemotherapy Resistant, Triple Negative Breast Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial of abemaciclib for surgically resectable, chemotherapy-resistant triple-negative breast cancer was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Triple-negative Breast Cancer

Drugs mentioned

• VERZENIO (ABEMACICLIB)

Snippet

Sponsor: Mayo Clinic | Conditions: Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8 | Phase 2 | Status: TERMINATED